Acarbose enhances human colonic butyrate production

被引:85
作者
Weaver, GA
Tangel, CT
Krause, JA
Parfitt, MM
Jenkins, PL
Rader, JM
Lewis, BA
Miller, TL
Wolin, MJ
机构
[1] MARY IMOGENE BASSETT HOSP, DEPT MED, COOPERSTOWN, NY 13326 USA
[2] CORNELL UNIV, ITHACA, NY 14853 USA
[3] NEW YORK STATE DEPT HLTH, WADSWORTH CTR LABS & RES, ALBANY, NY 12201 USA
关键词
acarbose; starch; propionic acid; butyric acid; humans; colonic fermentation; DEPENDENT DIABETES-MELLITUS; SIGMOIDOSCOPY POPULATION; ADENOMATOUS POLYPS; GENE-EXPRESSION; STARCH; FERMENTATION; CANCER; TRIAL; MULTICENTER; ASSOCIATION;
D O I
10.1093/jn/127.5.717
中图分类号
R15 [营养卫生、食品卫生]; TS201 [基础科学];
学科分类号
100403 ;
摘要
Earlier studies suggest that butyrate has colonic differentiating and nutritional effects and that acarbose increases butyrate production. To determine the effects of acarbose on colonic fermentation, subjects were given 50-200 mg acarbose or placebo (cornstarch), three times per day, with meals in a double-blind crossover study. Fecal concentrations of starch and starch-fermenting bacteria were measured and fecal fermentation products determined after incubation of fecal suspensions with and without added substrate for 6 and 24 h. Substrate additions were cornstarch, cornstarch plus acarbose and potato starch. Dietary starch consumption was similar during acarbose and placebo treatment periods, but fecal starch concentrations were found to be significantly greater with acarbose treatment. Ratios of starch-fermenting to total anaerobic bacteria were also significantly greater with acarbose treatment. Butyrate in feces, measured either as concentration or as percentage of total short-chain fatty acids, was significantly greater with acarbose treatment than with placebo treatment. Butyrate ranged from 22.3 to 27.5 mol/100 mol for the 50-200 mg, three times per day doses of acarbose compared with 18.3-19.3 mol/100 mol for the comparable placebo periods. The propionate in fecal total short-chain fatty acids was significantly less with acarbose treatment (10.7-12.1 mol/100 mol) than with placebo treatment (13.7-14.2 mol/100 mel). Butyrate production was significantly greater in fermentations in samples collected during acarbose treatment, whereas production of acetate and propionate was significantly less. Fermentation decreased when acarbose was added directly to cornstarch fermentations. Acarbose effectively augmented colonic butyrate production by several mechanisms; it reduced starch absorption, expanded concentrations of starch-fermenting and butyrate-producing bacteria and inhibited starch use by acetate- and propionate-producing bacteria.
引用
收藏
页码:717 / 723
页数:7
相关论文
共 23 条
[1]   CULTURAL METHODS AND SOME CHARACTERISTICS OF SOME OF THE MORE NUMEROUS GROUPS OF BACTERIA IN THE BOVINE RUMEN [J].
BRYANT, MP ;
BURKEY, LA .
JOURNAL OF DAIRY SCIENCE, 1953, 36 (03) :205-217
[2]   THE EFFICACY OF ACARBOSE IN THE TREATMENT OF PATIENTS WITH NON-INSULIN-DEPENDENT DIABETES-MELLITUS - A MULTICENTER CONTROLLED CLINICAL-TRIAL [J].
CHIASSON, JL ;
JOSSE, RG ;
HUNT, JA ;
PALMASON, C ;
RODGER, NW ;
ROSS, SA ;
RYAN, EA ;
TAN, MH ;
WOLEVER, TMS .
ANNALS OF INTERNAL MEDICINE, 1994, 121 (12) :928-935
[3]   COLONIC FERMENTATION OF DIETARY FIBER TO SHORT CHAIN FATTY-ACIDS IN PATIENTS WITH ADENOMATOUS POLYPS AND COLONIC-CANCER [J].
CLAUSEN, MR ;
BONNEN, H ;
MORTENSEN, PB .
GUT, 1991, 32 (08) :923-928
[4]   MULTICENTER, PLACEBO-CONTROLLED TRIAL COMPARING ACARBOSE (BAY G-5421) WITH PLACEBO, TOLBUTAMIDE, AND TOLBUTAMIDE-PLUS-ACARBOSE IN NON-INSULIN-DEPENDENT DIABETES-MELLITUS [J].
CONIFF, RF ;
SHAPIRO, J ;
SEATON, TB ;
BRAY, GA .
AMERICAN JOURNAL OF MEDICINE, 1995, 98 (05) :443-451
[5]  
Coniff Robert F., 1994, Archives of Internal Medicine, V154, P2442, DOI 10.1001/archinte.154.21.2442
[6]   EFFECTS OF ACARBOSE ON STARCH HYDROLYSIS - STUDY IN HEALTHY-SUBJECTS, ILEOSTOMY PATIENTS, AND INVITRO [J].
HIELE, M ;
GHOOS, Y ;
RUTGEERTS, P ;
VANTRAPPEN, G .
DIGESTIVE DISEASES AND SCIENCES, 1992, 37 (07) :1057-1064
[8]   COLONIC FERMENTATION AND MARKERS OF COLORECTAL-CANCER RISK [J].
KASHTAN, H ;
STERN, HS ;
JENKINS, DJA ;
JENKINS, AL ;
THOMPSON, LU ;
HAY, K ;
MARCON, N ;
MINKIN, S ;
BRUCE, WR .
AMERICAN JOURNAL OF CLINICAL NUTRITION, 1992, 55 (03) :723-728
[9]  
KRUH J, 1982, MOL CELL BIOCHEM, V42, P65
[10]  
*MERCK CO INC, 1983, ENCY CHEM DRUGS BIOL